Topical GHK-Cu has not been shown to improve aging skin in a controlled human trial. GHK-Cu is a copper-binding tripeptide sold in serums as "copper tripeptide-1" and, by prescription, as compounded creams and foams. As a cosmetic it generally needs no premarket approval, except for certain color additives as long as it makes no drug claims [7]. Compounded non-injectable GHK-Cu sits in Category 1 of FDA's 503A list, the group still under evaluation, as of the May 14, 2026 update [8].
Promising in the lab, thin in people
The selected studies below illustrate different products, populations and endpoints. The randomized laser-resurfacing study found no difference that blinded assessors could see [3].
| Study | Who | People | Design | What was measured | Result |
|---|---|---|---|---|---|
| Miller 2006 | Adults after CO2 laser resurfacing around the mouth | 13 completed | Randomized, regimen with vs without GHK-Cu | Redness by software and blinded raters; wrinkles and skin quality at 12 weeks | No difference between groups on objective measures; users rated skin quality better (P=.04) |
| Mulder 1994 | Adults with diabetic foot ulcers | Not given in the abstract | Multicenter, randomized, evaluator-blinded, vehicle-controlled | Ulcer closure | 98.5% vs 60.8% median closure (p<0.05); a wound-care result |
| Patel 2024 | Adults with mild to moderate dandruff | 32 enrolled, 29 completed | Open-label, single center, no control group, 15 days | Scalp flaking score | Flaking down 61%; product had 5 actives, so the effect can't be credited to GHK-Cu |
| Vignesh 2026 | Acne scars | 40 | Nonrandomized dermarolling add-on | Scar scores and pigmentation over 16 weeks | No later between-group advantage; 8/20 vs 0 pigmentation |
| Bo 2026 | Sparse eyebrows | 18 | Randomized split-face | Eyebrow count and diameter at 12 weeks | Reported improvement; small preliminary report |
Sources: PubMed records for each study. The 1994 trial's abstract does not give its enrollment.
These selected reports cover laser-treated skin, wound care and a mixed-ingredient scalp product; they are not an exhaustive inventory of topical studies. The claim-by-claim picture, including hair and injected use, is in does GHK-Cu work.
The laser-resurfacing randomized trial found no blinded difference
In a 2006 randomized trial after CO2 laser resurfacing, copper-peptide skin care did not speed the fading of redness or improve wrinkles on blinded ratings, compared with a regimen without it [3]. Redness was measured with computer image analysis and by evaluators who did not know the group. Wrinkles and overall skin appearance were judged at 12 weeks.
Everyone's skin improved after the laser, in both groups. The difference came from the patients themselves: on a validated questionnaire, people using the GHK-Cu products rated their overall skin quality as more improved (P=.04) [3]. The authors concluded that objective evaluation found no significant improvement, while satisfaction was higher with GHK-Cu.
Two limits matter. Thirteen people is too few to detect a modest effect, so the trial can't prove GHK-Cu does nothing. And freshly lasered skin is not the same as everyday aging skin, which is what most serums are bought for.
A diabetic-ulcer trial tested a different clinical setting
A multicenter, evaluator-blinded, placebo-controlled trial of a GHK-Cu gel reported 98.5% median closure of plantar diabetic ulcers, against 60.8% with the gel base alone [4]. Every patient also got a standardized wound-care program: debridement, pressure-relieving footwear and diabetes education. In ulcers treated right after debridement, infections ran 7% with the gel and 34% with the base.
This is a wound-care study of a drug-style gel, not a cosmetic trial. Open ulcers absorb and respond differently from intact facial skin. The abstract gives neither the number of patients nor the sponsor, so its abstract cannot establish precision, replication or general cosmetic benefit.
Newer topical reports answer narrower questions
A 40-person nonrandomized acne-scar study added copper peptide to dermarolling. Later between-group differences were not significant; hyperpigmentation occurred in 8 of 20 combination patients versus none with dermarolling alone. Allocation and baseline imbalance limit interpretation [1].
A preliminary 18-person randomized split-face report found eyebrow-count and diameter improvements after 12 weeks. Eyebrows, scalp hair and systemic injection claims are different questions; this result cannot answer them all [2].
Most GHK-Cu claims come from cells and animals
The well-known claims, such as more collagen and "resetting" thousands of genes, come from cell, animal and computer-based gene-expression work, not from skin trials in people. A 2015 narrative review lists wound healing in rats, mice, pigs and dogs and states that GHK can up- and downregulate at least 4,000 human genes [6]. Its authors work in the research department of Skin Biology, a company, and the review is not a systematic search.
Gene-expression results describe what a cell line does in a lab database. They show which genes move, not whether skin looks or works better. Treat any serum claim built on them as a hypothesis.
| Claim | Where it comes from | Human evidence |
|---|---|---|
| Builds collagen | Cell and animal studies | The reviewed selected clinical trials do not establish a general collagen benefit |
| Reduces wrinkles | Product marketing | One randomized trial, 13 people, no blinded difference |
| Heals wounds | Mulder 1994 | One diabetic-ulcer trial, an open-wound setting |
| Resets aging genes | Gene-expression reviews | Lab data only |
Match each claim to its clinical endpoint; a molecular effect is not a cosmetic effect.
Multi-ingredient products make results hard to read
Some recent human studies tested products that combine copper tripeptide-1 with other actives, so any effect can't be credited to GHK-Cu. In a 2024 open-label study, 29 adults finished 15 days of a hydroxy-acid scalp scrub plus a serum with copper tripeptide-1, witch hazel, hesperidin, hyaluronic acid and pea protein [5].
Flaking scores fell 61%, but there was no comparison group, and one author is employed by the product's maker, per the paper's disclosure [5]. When you see a study cited for a copper peptide product, check whether GHK-Cu was the only active and whether anyone got a placebo.
What the label on your serum tells you
Whether a copper peptide product is a cosmetic or a drug depends on what it claims to do. FDA's test is intended use: a product meant to cleanse or beautify is a cosmetic, while one meant to affect the structure or function of the body is a drug [7]. FDA gives "regenerate cells" and "restore hair growth" as examples of claims that make a product a drug, even if it is sold as a cosmetic.
Cosmetics, other than color additives, don't need FDA approval before they go on the market [7]. So a serum that says "copper tripeptide-1" on the box has not been tested by FDA for any skin benefit. Check the actual ingredient strength and formulation rather than assuming products are equivalent.
Prescription topical GHK-Cu is compounded, not FDA-reviewed
Prescription GHK-Cu creams and foams are made by compounding pharmacies, which FDA does not review product by product. Non-injectable GHK-Cu went back into Category 1 of FDA's 503A list on May 14, 2026, after nominations were briefly withdrawn in April. FDA plans to ask its compounding advisory committee about it before the end of February 2027 [8]. The full history is in is GHK-Cu FDA-approved, and the route-by-route rules are in GHK-Cu topical vs injected.
What it would take to call topical GHK-Cu proven
A convincing answer needs a larger randomized trial on ordinary aging skin, with the same cream minus GHK-Cu as the comparison. It should run long enough for skin to change, at least the 12 weeks Miller used, and measure wrinkles with blinded imaging rather than self-ratings alone [3].
- Enough people to detect a modest change, not 13.
- A vehicle control: the same base without the peptide.
- Blinded, objective measures such as standardized photos or skin imaging.
- A stated GHK-Cu strength, so the result applies to a product you can identify.
- Funding and author ties disclosed next to the result.
Larger trials on ordinary aging skin would make cosmetic claims easier to judge. A favorable response to a whole serum also does not identify which ingredient caused it. The positive eyebrow report and the ulcer result should retain their own product and outcome limits.
Category 1 describes a conditional interim enforcement policy; other legal requirements still apply. It is not a finding that a particular compounded product is safe, effective or lawfully supplied in every circumstance. Product-specific pharmacy and plan questions are explained in how we check providers.
ClinicalTrials.gov lists NCT07437586 as recruiting, with 60 estimated participants and no posted results. Its paired-wound protocol compares topical GHK-Cu gel with vehicle and plans healing and safety assessments. Registration is a research plan, not evidence that treatment works or is safe [9].